Evidence map›Paper›PMID 29527745›Full record

ArticleXenotransplantation2018

GalT-KO pig lungs are highly susceptible to acute vascular rejection in baboons, which may be mitigated by transgenic expression of hCD47 on porcine blood vessels.

Hironosuke Watanabe, Hisashi Sahara, Shunichiro Nomura, Tatsu Tanabe, Dilrukshi K Ekanayake-Alper, Lennan K Boyd, Nathan J Louras, Arsenoi Asfour, Makenzie A Danton, Siu-Hong Ho and 9 more

Abstract read
In one paragraph

Article in Xenotransplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 36 citations in OpenAlex.

  1. Transgenic expression of human CD47 on pig cells provides only partial protection against human macrophage-mediated destruction in human immune system mice.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  2. Review
  3. Pig Lung Xenotransplantation: Barriers on the Road to Clinical Translation.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Pig heart and lung xenotransplantation: Present status.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2022
    Article
  8. Article
  9. Article
  10. Pig-to-baboon lung xenotransplantation: Extended survival with targeted genetic modifications and pharmacologic treatments.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  11. Review
  12. Article
  13. Profiling HumanBiology · 2021
    Article
  14. Review
  15. Review
  16. Progress towards xenogenic tolerance.Current opinion in organ transplantation · 2020
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

Hironosuke WatanabeColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Hisashi SaharaDivision of Organ Replacement and Xenotransplantation Surgery, Center for Advanced Biomedical Science and Swine Research, Kagoshima University, Kagoshima, Japan.
Shunichiro NomuraColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Tatsu TanabeColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Dilrukshi K Ekanayake-AlperColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Lennan K BoydColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Nathan J LourasTransplantation Biology Research Laboratories, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Arsenoi AsfourColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Makenzie A DantonColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Siu-Hong HoColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Scott J ArnTransplantation Biology Research Laboratories, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Robert J HawleyColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Akira ShimizuDepartment of Analytic Human Pathology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Takeshi NagayasuDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
David AyaresRevivicor, Inc., Blacksburg, VA, USA.
Marc I LorberLung BioTechnology PBC, Silver Spring, MD, USA.
Megan SykesColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
David H SachsColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Kazuhiko YamadaColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.ORCID 0000-0002-0510-5843
Columbia University Irving Medical Center · USHarvard University · USKagoshima University · JPNagasaki University · JPNational Labor College · USNippon Medical School · JPVirginia Tech · US

Funding

XENOGRAFT TOLERANCE THROUGH MIXED CHIMERISMP01AI045897 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Megan Sykes · 2000 to 2026
$71.9M
Becton Dickinson LSR II Analytical Flow CytometerS10RR027050 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CLYNES, RAPHAEL A. · 2011 to 2011
$413k
Lung Biotechnology PBCNCRR NIH HHS S10 RR027050NIAID NIH HHS P01 AI045897NIH HHS P01AI45897
6 · The paper itself

Abstract

backgroundDespite recent progress in survival times of xenografts in non-human primates, there are no reports of survival beyond 5 days of histologically well-aerated porcine lung grafts in baboons. Here, we report our initial results of pig-to-baboon xeno-lung transplantation (XLTx).

methodsEleven baboons received genetically modified porcine left lungs from either GalT-KO alone (n = 3), GalT-KO/humanCD47(hCD47)/hCD55 (n = 3), GalT-KO/hD47/hCD46 (n = 4), or GalT-KO/hCD39/hCD46/hCD55/TBM/EPCR (n = 1) swine. The first 2 XLTx procedures were performed under a non-survival protocol that allowed a 72-hour follow-up of the recipients with general anesthesia, while the remaining 9 underwent a survival protocol with the intention of weaning from ventilation.

resultsLung graft survivals in the 2 non-survival animals were 48 and >72 hours, while survivals in the other 9 were 25 and 28 hours, at 5, 5, 6, 7, >7, 9, and 10 days. One baboon with graft survival >7 days, whose entire lung graft remained well aerated, was euthanized on POD 7 due to malfunction of femoral catheters. hCD47 expression of donor lungs was detected in both alveoli and vessels only in the 3 grafts surviving >7, 9, and 10 days. All other grafts lacked hCD47 expression in endothelial cells and were completely rejected with diffuse hemorrhagic changes and antibody/complement deposition detected in association with early graft loss.

conclusionsTo our knowledge, this is the first evidence of histologically viable porcine lung grafts beyond 7 days in baboons. Our results indicate that GalT-KO pig lungs are highly susceptible to acute humoral rejection and that this may be mitigated by transgenic expression of hCD47.

Indexed as

AnimalsAnimals, Genetically ModifiedCD47 AntigenGraft RejectionGraft SurvivalHeterograftsHumansLungLung TransplantationPapioSwineTransplantation, HeterologousTransplantsCD47 AntigenhCD47lung transplantationpig to baboonxenotransplantation

Identifiers

PMID29527745
PMCPMC6135720
OpenAlexW2794178355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.